期刊文献+

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice
下载PDF
导出
摘要 Rasagiline,a monoamine oxidase-B inhibitor,and bis(propyl)-cognitin(B3C),a novel dimer are reported to be neuroprotective.Herein,the synergistical neuroprotection produced by rasagiline and B3 C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced mice of Parkinsonism.By using neurobehavioural tests,high-performance liquid chromatography and western blot assay,we showed that B3 C at 0.3 mg/kg,rasagiline at 0.02 mg/kg,as well as co-treatment with B3 C and rasagiline prevented MPTP-induced behavioural abnormities,increased the concentrations of dopamine and its metabolites in the striatum,and up-regulated the expression of tyrosine hydroxylase in the substantia nigra.However,the neuroprotective effects of co-treatment were not significantly improved when compared with those of B3 C or rasagiline alone.Collectively,we have demonstrated that B3 C at 0.3 mg/kg and rasagline at 0.02 mg/kg could not produce synergistic neuroprotective effects. Rasagiline,a monoamine oxidase-B inhibitor,and bis(propyl)-cognitin(B3C),a novel dimer are reported to be neuroprotective.Herein,the synergistical neuroprotection produced by rasagiline and B3 C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced mice of Parkinsonism.By using neurobehavioural tests,high-performance liquid chromatography and western blot assay,we showed that B3 C at 0.3 mg/kg,rasagiline at 0.02 mg/kg,as well as co-treatment with B3 C and rasagiline prevented MPTP-induced behavioural abnormities,increased the concentrations of dopamine and its metabolites in the striatum,and up-regulated the expression of tyrosine hydroxylase in the substantia nigra.However,the neuroprotective effects of co-treatment were not significantly improved when compared with those of B3 C or rasagiline alone.Collectively,we have demonstrated that B3 C at 0.3 mg/kg and rasagline at 0.02 mg/kg could not produce synergistic neuroprotective effects.
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2016年第8期1339-1346,共8页 中国神经再生研究(英文版)
基金 supported by grants from the Natural Science Foundation of Guangdong Province of China,No.2015A030313317 a grant from the Science and Technology Program of Guangzhou City of China,No.2014J4100097 partially by a grant from the Science and Technology Development Fund(FDCT) of Macao Special Administrative Region,No.134/2014/A3 a grant from the Research Committee of University of Macao,No.MYRG139(Y1-L4)-ICMS12-LMY and MYRG2015-00214-ICMS-QRCM grants from the Research Grants Council of Hong Kong Special Administrative Region of China,No.561011,15101014 the Hong Kong Polytechnic University of China,No.G-SB10,G-UC15 and G-YBGQ
关键词 nerve regeneration Parkinson's disease bis(propyl)-cognitin RASAGILINE monoamine oxidase B DOPAMINE multitarget synergism NEUROPROTECTION neural regeneration nerve regeneration Parkinson's disease bis(propyl)-cognitin rasagiline monoamine oxidase B dopamine multitarget synergism neuroprotection neural regeneration
  • 相关文献

参考文献38

  • 1Ahlskog JE, Uitti RJ (2010) Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction? Neurology 74: 1143-1148.
  • 2Bao XQ, Kong XC, Qian C, Zhang D (2012) FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models. Neuroscience 202:396-404.
  • 3Bar-Am O, Weinreb O, Amit T, Youdim MBH (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19: 1899-1901.
  • 4Calabresi P, Di Filippo M (2015) Multitarget disease-modifying therapy in Parkinson's disease? Lancet Neurol 14:975-976.
  • 5Carlier PR, Han YF, Chow ES, Li CP, Wang H, Lieu TX, Wong HS, Pang YP (1999) Evaluation of short-tether Bis- THA AChE inhibitors. A further test of the dual binding site hypothesis. Biorg Med Chern 7:351-357.
  • 6Degli Esposti L, Piccinni C, Sangiorgi D, Nobili F, Buda S (2015) Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Neurol Sci 37:227-234.
  • 7Haavik J, Toska K (1998) Tyrosine hydroxylase and Parkinson's disease. Mol NeuroBiol16:285-309.
  • 8Han RW, Zhang RS, Chang M, Peng YL, Wang P, Hu SQ, Choi CL, Yin M, Wang R, Han YF (2012) Reversal of scopolamine-induced spatial and recognition memory deficits in mice by novel multifunctional dimers bis-cognitins. Brain Res 1470:59-68.
  • 9Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS (2004) Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 24:2045- 2053.
  • 10Hu SQ, Cui W, Xu DP, Mak SH, Tang J, Choi CL, Pang YP, Han YF (2013) Substantial neuroprotection against K+ deprivation-induced apoptosis in primary cerebellar granule neurons by novel dimer bis(propyl)-cognitin via the activation ofVEGFR-2 signaling pathway. CNS Neurosci Ther 19:764-772.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部